Top Rated Daytime Talk Show Features a Dramatic Zerona Makeover
Erchonia’s Low Level Laser Therapy Improves Breast Augmentation Procedures
Erchonia Corporation announced today the results of a double-blind randomized, placebo-controlled clinical study in which low level laser therapy was shown to significantly improve the post-surgical pain experienced after breast augmentation procedures.
The study found that of 99 female patients who had breast augmentations, 48 patients treated with the Erchonia laser reported their pain was 77% less then the 51 patients who received a placebo therapy. Results also showed the laser therapy curbed swelling and edema making for a shortened recovery process. Patients received the noninvasive laser therapy for 4 minutes before the procedure, 4 minutes immediately after the procedure and again 24 hours later.Charlie Shanks, VP of Erchonia, comments, “This study’s results are similar to those of previous studies that led to the Erchonia laser’s FDA approval for use during liposuction procedures and for chronic neck and shoulder pain. We are delighted that our laser technology has yet again shown to improve the quality of patient recovery after surgery.”
In contrast to the high-power, high-heat lasers that are used in various surgical procedures, Erchonia lasers produce a low-level, or cold, output that has no thermal effect on the body’s tissue. Instead, the laser serves to stimulate biological function.
For Information Contact:
Charlie Shanks
VP Sales & Marketing
888.242.0571
cshanks@erchonia.com
FOR IMMEDIATE RELEASE:
According to the National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS) nearly 17 million people in the United States have acne, making it the most common skin disease. Teenagers and adults alike now have a weapon to battle this disease through new laser technology, DermaLASER™, approved by the U.S. Food and Drug Administration (FDA).
The DermaLASER™ created by Arizona-based Erchonia is a low-level, or cold, laser that works by killing the bacteria P. Acnes that causes acne. Unlike current acne-laser treatments, the DermaLASER™ is not high density, or hot, so it does not irritate or adversely affect the healthy skin cells. The DermaLASER™ isolates and targets the acne-causing bacteria itself, not the skin, so it effectively treats the cause of acne at its root.
“There is no single disease linked to as much psychosocial trauma as acne,” according to Charlie Shanks, Vice President of Erchonia. “It is our hope that the DermaLASER™, because of its fast and proven results, will change the lives of literally millions of these people battling the social impacts of acne. I think acne has finally met its match.”
Up until now, people with acne have had to rely on strong antibiotic treatments lasting several months, harsh topical ointments that can irritate and severely dry out the skin or hot lasers that cause redness and pain. 30 years of research shows that side-effects from low-level laser treatments of all kinds are minimal to non-existent and the DermaLASER™ is no exception.
Erchonia, the company that created DermaLASER™, is the leader in low-level laser technology. DermaLASER™ is the latest in a series of low-level laser treatments that are used for everything from pain relief to aiding in liposuction surgery. To learn more about Erchonia and their products, go to www.erchonia.com.
For Information Contact:
Erchonia Corporation
2021 Commerce Drive
McKinney, TX 75071
ATT: Charlie Shanks
VP, Sales and Marketing
214.733.5203
cshanks@erchonia.com
Erchonia Corporation, a world leader in the research, design, development, and manufacturing of low-level lasers announced that the US Food and Drug Administration has approved its 4L™ laser for use during liposuction.
The Erchonia 4L™ laser is the first and only low-level laser approved for use during liposuction. The painless laser treatment is administered a few minutes prior to liposuction and works by liquefying the fat. As a result, fat removal is made easier and quicker. There is less post-op pain and bruising and a speedier recovery time. In addition less pain medication is required.
The FDA approved the laser based on the results of an IRB approved, multi-center, double blind, randomized study. The comparison between the actively treated patients and the placebo-treated patients resulted in an impressive difference between groups in degree of pain. Significant differences in emulsification of fat, ease of extraction, and amount of swelling were also recorded.
“This approval is a major step forward in our goal to establish the Erchonia 4L™ laser as the future of liposuction,” comments Charlie Shanks, VP of Sales and Marketing for Erchonia Corporation. “We believe that eventually patients will demand laser-assisted liposuction over traditional methods because of the amazing post-operative benefits.”
Erchonia was founded in 1996 and is dedicated to advancing the science of health through the development of superior bio-medical laser products. Recently, Erchonia moved into a new state of the art facility where research, development, fabrication and assembly of goods are completed in-house. Erchonia also has FDA approval on the use of their lasers for therapeutic healing.
The Erchonia laser is currently being used by approximately 100 cosmetic and plastic surgeons. To find a surgeon or for more information on Erchonia, visit www.erchonia.com.
For Information Contact:
Charlie Shanks
VP Sales & Marketing
(480) 633-3129
cshanks@erchonia.com
FOR IMMEDIATE RELEASE:
Erchonia Medical, Inc. announces that on June 8, 2004 the United States Patent Office issued U.S. Patent No. 6,746,473 to Erchonia Medical, Inc. covering all hand-held laser devices with more than one laser.
This enables Erchonia Medical, Inc., to offer the only patented, handheld, true multi-laser devices as compared to various other “multi-LED” devices that often claim to be lasers, when in fact, they are not. Multi-diode laser components enhance the efficiency and effectiveness of the devices in which they are utilized.
“This patent is a testament to Erchonia’s continuing commitment to be the world leader in low level laser technology and to consistently push the boundaries of physics, technology and medical applications to seek the answers to human pain and suffering,” states Charlie Shanks, VP of Sales and Marketing.
“Erchonia has consistently lead the world in state-of-the-art healing laser technology and manufacturing, from our very earliest products to our present PL4000 and PL5000 lasers that are in use throughout the world today.”
“Erchonia was the very first low level laser manufacturer to receive the FDA’s 510(k) market clearance for the treatment of chronic pain, and in addition to this patent, Erchonia is anticipating a second FDA clearance this summer,” says Mr. Shanks.
Erchonia 3LT™ Lasers are small hand held devices that are being utilized by health care professionals and professional sports organizations worldwide for the treatment of a wide range of conditions from acute and chronic pain to wound and burn healing.
Erchonia Medical, Inc., is the world leader in the research, design and manufacturing of Low Level Lasers and proudly displays the MADE IN THE USA label on all of their products produced at their world headquarters in Mesa, AZ.
About Erchonia
Founded in 1996 to advance the art and science of health through the development, and distribution of superior Erchonia® 3LT™ lasers. Erchonia is dedicated to the highest quality standards, evidenced by their ISO 9000 and ISO 13000 manufacturing standards. They have built an impeccable reputation in the sports market, working with several professional organizations such as the New York Jets, Kansas City Chiefs, Philadelphia 76ers and the Milwaukee Brewers to name a few. Erchonia’s manufacturing facility is located at 4751 E. Indigo Street, Mesa, AZ 85205. All parts of the Erchonia® 3LT™ Laser are made in the USA.
For more information on Erchonia, please visit their web site at www.erchonia.com.
6 NEWS – First at 5:00 – Dr. Robert Jackson, clinical trial principal investigator, talks about Zerona™ and the results shown in the study.
